Current Report Filing (8-k)
September 24 2020 - 8:36AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(D)
of the Securities Exchange Act of 1934
Date of report (Date of earliest event
reported): September 24, 2020
Leap Therapeutics, Inc.
(Exact name of registrant as specified
in its charter)
Delaware
|
001-37990
|
27-4412575
|
(State
or other jurisdiction
of incorporation)
|
(Commission
File Number)
|
(IRS Employer
Identification No.)
|
47
Thorndike Street, Suite B1-1
Cambridge,
MA
|
02141
|
(Address
of principal executive offices)
|
(Zip
Code)
|
Registrant’s
telephone number, including area code: (617) 714-0360
N/A
(Former name or former
address, if changed since last report)
Check the appropriate box below if the
Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
|
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).
|
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).
|
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).
|
Securities registered pursuant to Section 12(b) of the Act:
Title
of each class
|
Trading
Symbol(s)
|
Name
of each exchange on which
registered
|
Common
Stock, par value $0.001
|
LPTX
|
Nasdaq
Global Market
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter)
Emerging growth company x
If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 8.01. Other Events
On September 24, 2020, Leap Therapeutics,
Inc. (the “Company”) issued a press release entitled “Leap Therapeutics Announces FDA Fast Track Designation
Granted to DKN-01 for the Treatment of Gastric and Gastroesophageal Junction Cancer.”
The full text of the press release is
filed as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference; provided, however that information
on or connected to our website referenced in the Company’s press release is expressly not incorporated by reference into
or intended to be filed as a part of this Current Report on Form 8-K.
|
Item 9.01.
|
Financial Statements
and Exhibits.
|
(d) Exhibits.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
Dated: September 24, 2020
|
By:
|
/s/ Douglas E. Onsi
|
|
Name:
|
Douglas E. Onsi
|
|
Title:
|
Chief Executive Officer and President
|
Leap Therapeutics (NASDAQ:LPTX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Leap Therapeutics (NASDAQ:LPTX)
Historical Stock Chart
From Sep 2023 to Sep 2024